logo
Plus   Neg
Share
Email

Oracle Says Appeals Court Affirms Injunction Against Rimini Street

Oracle Corp. (ORCL) Monday said an appeals court rejected Rimini Street's attempt to avoid the District Court's injunction barring Rimini Street from engaging in conduct that infringes Oracle's intellectual property rights.

The Appeals Court also affirmed the trial court's $28.5 million attorneys' fees award to Oracle, rejecting Rimini's absurd claim that it had prevailed at a trial where the jury found Rimini infringed Oracle's copyrights.

Rimini Street has paid more than $90 million to Oracle as a result of that infringement, and the trial court issued a permanent injunction.

"We are extremely gratified that the Ninth Circuit affirmed the permanent injunction and attorneys' fees award. It is long past time for Rimini -- a dishonest, serial infringer -- to cease its unlawful conduct, to respect Oracle's intellectual property rights, and to abide by the rulings in this case," said Dorian Daley, Oracle's Executive Vice President and General Counsel.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the fourth quarter on Tuesday, Lockheed Martin Corp. (LMT) initiated earnings outlook for the full-year 2020, while boosting annual net sales outlook. For fiscal 2020, the company now expects earnings in a range of $23.65 to $23.95 per share. Net sales are now... Pfizer Inc. (PFE) reported that its fourth-quarter adjusted earnings per share declined 13 percent year-over-year to $0.55. On average, 11 analysts polled by Thomson Reuters expected the company to report profit per share of $0.57, for the quarter. Analysts' estimates typically exclude special items.... Practice Fusion Inc., a cloud-based electronic health record or EHR platform, agreed to pay $145 million to resolve criminal and civil investigations relating to its EHR software, the U.S. Department of Justice said in a statement. The company allegedly received kickbacks for increasing opioid prescriptions.
Follow RTT
>